Article focus {#section5-2046-3758.612.BJR-2017-0102.R1}
=============

-   The objective of this study was to identify key genes in osteoporosis.

Key messages {#section6-2046-3758.612.BJR-2017-0102.R1}
============

-   Genes including VPS35, FCGR2A, TBCA, HIRA, TYROBP, JUND, PHF20, NFKB2, RPL35A and BICD2 were considered to play potential roles in the pathology of osteoporosis.

Strengths and limitations {#section7-2046-3758.612.BJR-2017-0102.R1}
=========================

-   Bioinformatics analysis was used to identify and study the biological function of differentially expressed genes.

-   The validation sample for quantitative reverse transcriptase-polymerase chain reaction was small and it is necessary to collect larger samples for further validation.

Introduction {#section8-2046-3758.612.BJR-2017-0102.R1}
============

Osteoporosis, characterised by the impairment of bone microarchitecture and the loss of bone mass and strength, has become an important clinical problem in ageing populations.^[@bibr1-2046-3758.612.BJR-2017-0102.R1],[@bibr2-2046-3758.612.BJR-2017-0102.R1]^ The spine is the most common site of osteoporotic fractures, followed by the hip, forearm and proximal humerus.^[@bibr3-2046-3758.612.BJR-2017-0102.R1]^ Osteoporosis is characterised by deterioration of the microstructure of bone, specifically at trabecular sites, which leads to pain, deformity, disability and possibly death.^[@bibr4-2046-3758.612.BJR-2017-0102.R1],[@bibr5-2046-3758.612.BJR-2017-0102.R1]^ A variety of factors contribute to the development of osteoporosis, such as genetic variants, gender, steroid production, age, lifestyle and environment.^[@bibr6-2046-3758.612.BJR-2017-0102.R1]-[@bibr8-2046-3758.612.BJR-2017-0102.R1]^ Additionally, low calcium intake, cigarette-smoking and intake of excessive alcohol may be secondary causes.^[@bibr4-2046-3758.612.BJR-2017-0102.R1],[@bibr9-2046-3758.612.BJR-2017-0102.R1]^ Generally, osteoporosis is considered a silent disease because it is asymptomatic until a fracture occurs. Recently, the treatment of osteoporosis has been mainly pharmaceutical, but treatment may not be satisfactory due to its time-consuming nature and high cost, as well as the side effects of the drugs.

As Sims et al^[@bibr10-2046-3758.612.BJR-2017-0102.R1]^ have reported, a number of studies have explored the mechanism of osteoporosis. The members of the Wnt signalling pathway, such as Wnt3a, low-density lipoprotein receptor-related protein 5, secreted frizzled-related protein 1 and sclerostin, have been suggested to be related to variation in bone mineral density (BMD).^[@bibr10-2046-3758.612.BJR-2017-0102.R1]^ It is known that osteoporosis is defined clinically by measuring the BMD with heritability estimates of 0.5 to 0.9.^[@bibr11-2046-3758.612.BJR-2017-0102.R1]^ This further demonstrated that BMD is an important clinical marker in osteoporosis. The underlying aetiology of osteoporosis is still not fully understood and the identification of novel therapeutic target genes for osteoporosis is needed.

It is worth mentioning that microarray data analysis is available to identify vital genes and gene regulatory networks associated with disease.^[@bibr12-2046-3758.612.BJR-2017-0102.R1]^ In this study, we downloaded the data sets GSE56815 and GSE56814 from the Gene Expression Omnibus database, and identified the differentially expressed genes (DEGs) in blood samples obtained from osteoporosis patients, followed by Gene Ontology (GO)^[@bibr13-2046-3758.612.BJR-2017-0102.R1]^ and Kyoto Encyclopedia of Genes and Genomes (KEGG)^[@bibr14-2046-3758.612.BJR-2017-0102.R1]^ enrichment analyses and interaction network construction between transcription factors (TFs) and DEGs. We aimed to find involvement of key genes in osteoporosis which may be potential modulators in the pathology of osteoporosis.

Methods {#section9-2046-3758.612.BJR-2017-0102.R1}
=======

Microarray data {#section10-2046-3758.612.BJR-2017-0102.R1}
---------------

The two microarray data sets (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56815> and <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56814>) were downloaded using the GEOquery package with R version (The R Foundation for Statistical Computing, Vienna, Austria) from the Gene Expression Omnibus (GEO) database. These two microarray data sets were from the blood samples of 67 osteoporosis patients (based on World Health Organization (WHO) criteria) and 62 control groups. It is reported that the WHO recommends the use of BMD of the spine and proximal femur measured by double energy X-ray absorption as the benchmark to diagnose osteoporosis and its severity.^[@bibr15-2046-3758.612.BJR-2017-0102.R1]^ Therefore, diagnosis of osteoporosis depended on the BMD in these two datasets; these osteoporosis patients all had low BMD. In addition, the patients with osteoporosis did not receive any anti-osteoporosis medication or other medication that may affect bone metabolism. Detailed information of two data sets is shown in [Table I](#table1-2046-3758.612.BJR-2017-0102.R1){ref-type="table"}.

###### 

Two Gene Expression Omnibus (GEO) datasets of osteoporosis

  Gene type   GEO ID     Platform                                                                                   Sample count (control group: patients with osteoporosis)   Notes
  ----------- ---------- ------------------------------------------------------------------------------------------ ---------------------------------------------------------- -------------------------------------------------------------
  mRNA        GSE56815   GPL96 \[HG-U133A\] Affymetrix Human Genome U133A Array                                     80 (40:40)                                                 Liu YZ, USA, 2016^[@bibr16-2046-3758.612.BJR-2017-0102.R1]^
  mRNA        GSE56814   GPL5175 \[HuEx-1_0-st\] Affymetrix Human Exon 1.0 ST Array \[transcript (gene) version\]   49 (22:27)                                                 Liu YZ, USA, 2016^[@bibr16-2046-3758.612.BJR-2017-0102.R1]^

mRNA, messenger ribonucleic acid

Screening of DEGs {#section11-2046-3758.612.BJR-2017-0102.R1}
-----------------

Normalised microarray data were downloaded and gene expression value was calculated as the mean value of its corresponding probe values. Limma package^[@bibr17-2046-3758.612.BJR-2017-0102.R1]^ and Meta-MA^[@bibr18-2046-3758.612.BJR-2017-0102.R1]^ package were used to identify the DEGs between osteoporosis and control group; p-values and false discovery rates (FDR) were further calculated. FDR \< 0.01 was selected as the threshold for screening DEGs.

Functional analyses of DEGs {#section12-2046-3758.612.BJR-2017-0102.R1}
---------------------------

GO and KEGG enrichment analyses were carried out for the identified DEGs using GeneCodis3 (<http://www.genecodis.cnb.csic.es/analysis>).^[@bibr19-2046-3758.612.BJR-2017-0102.R1]-[@bibr21-2046-3758.612.BJR-2017-0102.R1]^ Significant GO terms and KEGG pathways were identified according to the threshold of p \< 0.05.

Network construction of DEGs and TFs {#section13-2046-3758.612.BJR-2017-0102.R1}
------------------------------------

To gain deeper insight into the molecular functions of DEGs, the gene regulatory relationships between DEGs and TFs were selected based on human TF binding sites data and genetic coordinate position information, which were available at the UCSC ENCODE Genome Browser.^[@bibr22-2046-3758.612.BJR-2017-0102.R1]^ The identified TFs were considered to be associated with DEGs and the regulatory network between DEGs and TFs was visualised using Cytoscape software (Cytoscape Corporation, San Diego, California).

Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) *in vitro* {#section14-2046-3758.612.BJR-2017-0102.R1}
---------------------------------------------------------------------------------

Four women diagnosed with osteoporosis with low BMD were enrolled in this study, as were three women with high BMD but no diagnosis of osteoporosis. The clinical information of osteoporosis patients is shown in [Table II](#table2-2046-3758.612.BJR-2017-0102.R1){ref-type="table"}. All blood samples were collected for further qRT-PCR experimentation. All participating individuals provided informed consent with the approval of the ethics committee.

###### 

The clinical information of osteoporosis patients

  Patient number   Gender   Age (yrs)   Weight (kg)   Height (cm)   Smoking history   Drinking history   Family history   Menopause status   BMD     Diagnostic method   Symptom
  ---------------- -------- ----------- ------------- ------------- ----------------- ------------------ ---------------- ------------------ ------- ------------------- ----------------------
  1                Female   82          50            160           No                No                 No               Yes                -2.57   DXA                 Elderly osteoporosis
  2                Female   81          45            155           No                No                 No               Yes                -2.66   DXA                 Elderly osteoporosis
  3                Female   72          55            163           No                No                 No               Yes                -2.93   DXA                 Elderly osteoporosis
  4                Female   66          60            165           No                No                 No               Yes                -2.82   DXA                 Elderly osteoporosis
  5                Female   69          53            158           No                No                 No               Yes                -0.49   DXA                 Normal
  6                Female   79          46            162           No                No                 No               Yes                -0.58   DXA                 Normal
  7                Female   73          57            157           No                No                 No               Yes                -0.43   DXA                 Normal

BMD, bone mineral density; DXA, double energy X-ray absorption

Total ribonucleic acid (RNA) of the blood samples was extracted using TRIzol Reagent (Invitrogen, Carlsbad, California), in accordance with the manufacturer's protocols. Then 1 ug RNA was applied to synthesise DNA by SuperScript III Reverse Transcriptase (Invitrogen) and qRT-PCR was performed in an ABI 7500 Real-time PCR system (Invitrogen) with SYBR Green PCR Master Mix (Invitrogen). Glyceraldehyde 3-phosphate dehydrogenase was used as internal control and all reactions were performed in triplicate. Relative gene expressions were analysed by the 2^-△△Ct^ method.

Receiver operating characteristic (ROC) analyses {#section15-2046-3758.612.BJR-2017-0102.R1}
------------------------------------------------

By using the pROC package^[@bibr23-2046-3758.612.BJR-2017-0102.R1]^ in R language, we performed the ROC analyses to assess the diagnostic value of DEGs. The area under the curve (AUC) under the binomial exact confidence interval was calculated and the ROC curve was generated.

Results {#section16-2046-3758.612.BJR-2017-0102.R1}
=======

DEGs identification {#section17-2046-3758.612.BJR-2017-0102.R1}
-------------------

In this study, we identified 1320 DEGs with significantly altered expression in osteoporosis blood samples, of which 855 were up-regulated and 465 were down-regulated compared with the control groups. The top 20 (ten up-regulated and ten down-regulated) DEGs abbreviations are defined in [Table III](#table3-2046-3758.612.BJR-2017-0102.R1){ref-type="table"} and presented in [Table IV](#table4-2046-3758.612.BJR-2017-0102.R1){ref-type="table"}. The results indicated that the expression pattern of these DEGs could observably distinguish the osteoporosis samples from control groups.

###### 

Differentially expressed gene abbreviations

  Abbreviation   Full name
  -------------- --------------------------------------------------------
  ALKBH1         alkB homolog 1, histone H2A dioxygenase
  BICD2          BICD cargo adaptor 2
  CDKN2D         cyclin dependent kinase inhibitor 2D
  DPP8           dipeptidyl peptidase 8
  FCGR2A         Fc fragment of IgG receptor IIa
  HIRA           histone cell cycle regulation
  IER2           immediate early response 2
  JUND           JunD proto-oncogene, AP-1 transcription factor subunit
  METTL4         methyltransferase like 4
  NBEAL2         neurobeachin like 2
  NFKB2          nuclear factor kappa B subunit 2
  NIF3L1         NGG1 interacting factor 3 like 1
  NIT2           nitrilase family member 2
  PAF1           PAF1 homolog, Paf1/RNA polymerase II complex component
  PHF20          PHD finger protein 20
  POGLUT1        protein O-glucosyltransferase 1
  RPL35A         ribosomal protein L35a
  SAP130         Sin3A associated protein 130
  SH3GLB2        SH3 domain containing GRB2 like, endophilin B2
  TBCA           tubulin folding cofactor A
  TYROBP         TYRO protein tyrosine kinase binding protein
  VPS35          VPS35, retromer complex component

###### 

The top 20 differentially expressed genes (DEGs) in osteoporosis

  ID      Symbol    Combined ES   p-value    FDR        Regulation
  ------- --------- ------------- ---------- ---------- ------------
  55737   VPS35     1.41E+00      5.58E-13   4.37E-09   Up
  56983   POGLUT1   1.40E+00      7.55E-13   4.37E-09   Up
  54878   DPP8      1.39E+00      1.32E-12   5.09E-09   Up
  60491   NIF3L1    1.31E+00      1.32E-11   3.81E-08   Up
  51230   PHF20     1.25E+00      9.79E-11   2.03E-07   Up
  56954   NIT2      1.26E+00      1.05E-10   2.03E-07   Up
  64863   METTL4    1.21E+00      1.77E-10   2.92E-07   Up
  79595   SAP130    1.21E+00      3.95E-10   5.71E-07   Up
  2212    FCGR2A    1.16E+00      1.32E-09   1.70E-06   Up
  8846    ALKBH1    1.17E+00      2.41E-09   2.79E-06   Up
  4791    NFKB2     -1.06E+00     1.97E-08   6.92E-06   Down
  6165    RPL35A    -1.07E+00     2.51E-08   7.98E-06   Down
  23299   BICD2     -1.05E+00     2.55E-08   7.98E-06   Down
  6902    TBCA      -1.07E+00     2.88E-08   8.35E-06   Down
  56904   SH3GLB2   -1.03E+00     3.04E-08   8.58E-06   Down
  7290    HIRA      -1.02E+00     3.50E-08   9.22E-06   Down
  54623   PAF1      -1.03E+00     3.76E-08   9.68E-06   Down
  23218   NBEAL2    -1.05E+00     4.25E-08   1.07E-05   Down
  9592    IER2      -1.02E+00     5.34E-08   1.19E-05   Down
  1032    CDKN2D    -1.07E+00     6.00E-08   1.24E-05   Down

ES, effect size; FDR, false discovery rate

GO and KEGG analyses of DEGs {#section18-2046-3758.612.BJR-2017-0102.R1}
----------------------------

Among 1320 DEGs, 1251 genes were recognised and significantly involved in different GO terms and KEGG pathways. The top 15 enriched GO terms, such as biological process, molecular function and cellular component of the identified DEGs are shown in [Table V](#table5-2046-3758.612.BJR-2017-0102.R1){ref-type="table"}. The results showed that these DEGs were mainly involved in the GO terms associated with apoptosis processes, gene expression and signal transduction. On the other hand, the results of KEGG analysis revealed that a total of 15 pathways were enriched; for example, Ubiquitin mediated proteolysis and osteoclast differentiation ([Table VI](#table6-2046-3758.612.BJR-2017-0102.R1){ref-type="table"}).

###### 

Top 15 enriched Gene Oncology (GO) terms in osteoporosis

  GO ID        GO term                                                                                   Genes (n)   FDR
  ------------ ----------------------------------------------------------------------------------------- ----------- ----------
               **Biological process**                                                                                
  GO:0006915   Apoptotic process                                                                         75          2.26E-17
  GO:0010467   Gene expression                                                                           56          2.31E-14
  GO:0007165   Signal transduction                                                                       105         2.99E-14
  GO:0015031   Protein transport                                                                         50          9.06E-11
  GO:0006355   Regulation of transcription, DNA-dependent                                                119         1.16E-10
  GO:0006810   Transport                                                                                 61          4.45E-10
  GO:0048011   Nerve growth factor receptor signalling pathway                                           33          1.19E-09
  GO:0016070   RNA metabolic process                                                                     36          1.73E-09
  GO:0016032   Viral reproduction                                                                        41          2.23E-09
  GO:0044419   Interspecies interaction between organisms                                                41          2.24E-09
  GO:0008380   RNA splicing                                                                              36          3.86E-09
  GO:0042981   Regulation of apoptotic process                                                           31          4.62E-09
  GO:0000278   Mitotic cell cycle                                                                        38          8.32E-09
  GO:0016071   mRNA metabolic process                                                                    32          8.35E-09
  GO:0051437   Positive regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle   18          9.82E-09
               **Molecular function**                                                                                
  GO:0005515   Protein binding                                                                           446         2.10E-93
  GO:0000166   Nucleotide binding                                                                        180         7.43E-24
  GO:0003677   DNA binding                                                                               142         4.86E-16
  GO:0005524   ATP binding                                                                               126         5.21E-16
  GO:0046872   Metal ion binding                                                                         193         1.71E-14
  GO:0003723   RNA binding                                                                               69          5.81E-14
  GO:0016787   Hydrolase activity                                                                        90          1.13E-13
  GO:0016740   Transferase activity                                                                      59          2.82E-09
  GO:0008270   Zinc ion binding                                                                          129         3.94E-09
  GO:0003676   Nucleic acid binding                                                                      68          2.21E-08
  GO:0003700   Sequence-specific DNA binding transcription factor activity                               71          1.04E-07
  GO:0016874   Ligase activity                                                                           40          1.10E-07
  GO:0003824   Catalytic activity                                                                        37          3.27E-06
  GO:0008233   Peptidase activity                                                                        44          4.47E-06
  GO:0042803   Protein homodimerisation activity                                                         45          5.19E-06
               **Cellular component**                                                                                
  GO:0005737   Cytoplasm                                                                                 464         3.22E-78
  GO:0005634   Nucleus                                                                                   457         4.04E-71
  GO:0005829   Cytosol                                                                                   246         6.44E-58
  GO:0005739   Mitochondrion                                                                             155         1.62E-33
  GO:0005654   Nucleoplasm                                                                               116         6.90E-31
  GO:0016020   Membrane                                                                                  295         3.54E-30
  GO:0005730   Nucleolus                                                                                 141         3.18E-24
  GO:0005622   Intracellular                                                                             156         2.02E-18
  GO:0005794   Golgi apparatus                                                                           97          7.96E-18
  GO:0005783   Endoplasmic reticulum                                                                     99          1.43E-17
  GO:0005789   Endoplasmic reticulum membrane                                                            73          4.91E-16
  GO:0016021   Integral to membrane                                                                      259         8.22E-14
  GO:0005743   Mitochondrial inner membrane                                                              43          2.07E-12
  GO:0005625   Soluble fraction                                                                          44          1.45E-09
  GO:0000139   Golgi membrane                                                                            46          1.55E-09

FDR, false discovery rate; RNA, ribonucleic acid; mRNA, messenger RNA; ATP, adenosine triphosphate

###### 

Top 15 enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) terms in osteoporosis

  KEGG ID    KEGG term                                     Count   FDR        Genes
  ---------- --------------------------------------------- ------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hsa04120   Ubiquitin mediated proteolysis                24      2.83E-08   UBE2A,MDM2,HERC1,UBE2Z,UBE4B,FZR1,DET1,CDC23,FBXO4,ANAPC2,ANAPC13,CDC27,UBE2W,UBE2G1,NEDD4,SOCS3,UBE2D3,UBE2E3,UBE4A,VHL,CUL1,UBE2D4,UBE2N,HERC2
  Hsa04380   Osteoclast differentiation                    22      1.18E-07   TYROBP,NFKB2,JUND,IL1R1,TYK2,NFKBIA,CREB1,TNFRSF1A,PPP3CC,LILRB3,SOCS3,FOSB,CYBB,FCGR2A,NFKB1,LILRA2,JUN,MITF,MAPK14,JUNB,PIK3CG,IFNAR1
  Hsa05016   Huntington\'s disease                         26      1.32E-07   POLR2J,NDUFA8,ATP5G1,COX6A2,POLR2H,POLR2B,NDUFC1,CREB1,COX5B,NRF1,GRIN2B,PLCB3,GNAQ,TBP,UQCRC2,NDUFA7,UQCR10,NDUFA13,BAX,NDUFB1,SDHD,PPARGC1A,NDUFB5,NDUFS3,SDHA,ATP5B
  Hsa00190   Oxidative phosphorylation                     22      1.45E-07   NDUFA8,ATP5G1,COX6A2,NDUFC1,COX10,COX5B,ATP5L,ATP5I,ATP6V1E1,ATP6V0E2,UQCRC2,NDUFA7,UQCR10,NDUFA13,NDUFB1,SDHD,NDUFB5,ATP6V1B2,NDUFS3,SDHA,LHPP,ATP5B
  Hsa04141   Protein processing in endoplasmic reticulum   24      1.76E-07   SEC63,SSR2,UBE4B,CANX,ATF6,RPN2,SSR4,PPP1R15A,STT3A,UBE2G1,UBE2D3,UBE2E3,RRBP1,PDIA6,CUL1,BAX,UBE2D4,HERPUD1,SEL1L,DNAJC10,EIF2S1,LMAN2,MBTPS2,SIL1
  Hsa04142   Lysosome                                      20      5.87E-07   NPC2,SCARB2,CTSC,GLA,LAPTM4A,MANBA,CLN5,FUCA1,AGA,LIPA,ASAH1,NPC1,PPT1,ARSB,HEXB,DNASE2,CTSO,IDS,IGF2R,LAPTM5
  Hsa05010   Alzheimer\'s disease                          23      9.66E-07   NDUFA8,ATP5G1,COX6A2,NDUFC1,IDE,ATF6,TNFRSF1A,COX5B,PPP3CC,GRIN2B,ITPR2,PLCB3,GNAQ,UQCRC2,NDUFA7,UQCR10,NDUFA13,NDUFB1,SDHD,NDUFB5,NDUFS3,SDHA,ATP5B
  Hsa00020   Citrate cycle (TCA cycle)                     10      1.50E-06   CS,DLAT,IDH3A,SDHD,MDH1,DLST,ACO2,SDHA,PDHB,SUCLG2
  Hsa03040   Spliceosome                                   19      1.54E-06   SF3A3,WBP11,PRPF6,RBM17,DHX38,PPIE,TXNL4A,PRPF38B,EIF4A3,PRPF3,RBM25,SART1,SRSF3,CDC5L,CRNKL1,ACIN1,LSM3,SNRNP40,SNRPB2
  Hsa03050   Proteasome                                    11      2.77E-06   SHFM1,PSMC2,PSMD11,PSMC4,PSME3,PSMB3,PSMD1,PSMD2,PSME1,PSMD8,PSMA4
  Hsa00970   Aminoacyl-tRNA biosynthesis                   10      2.27E-05   IARS,DARS2,RARS,WARS,DARS,GARS,NARS2,NARS,WARS2,EPRS
  Hsa05200   Pathways in cancer                            31      2.43E-05   VEGFB,MDM2,SOS1,NFKB2,ARNT,HRAS,CCNE1,NFKBIA,E2F1,CCND1,PTEN,TPM3,RALB,BCR,RALBP1,CTBP1,CTBP2,FZD2,NFKB1,TFG,JUN,VHL,FLT3,MAP2K2,MITF,BAX,VEGFC,SOS2,PIK3CG,MLH1,DVL1
  Hsa03013   RNA transport                                 19      2.53E-05   EIF2S3,RPP30,EIF3H,NUP98,PRMT5,POM121,EIF3D,NUP43,NUP155,NXT2,EIF3G,RPP38,EIF4E2,EIF4A3,SNUPN,POP4,EIF2S1,ACIN1,EIF3E
  Hsa05220   Chronic myeloid leukemia                      13      3.34E-05   MDM2,SOS1,HRAS,NFKBIA,E2F1,CCND1,BCR,CTBP1,CTBP2,NFKB1,MAP2K2,SOS2,PIK3CG
  Hsa04144   Endocytosis                                   22      3.68E-05   MDM2,CXCR4,SH3GLB2,ADRB2,RAB11FIP5,HRAS,FOLR2,ADRBK1,RAB11FIP3,GRK6,TSG101,ARAP1,NEDD4,HGS,PARD6A,SRC,RAB5C,RAB5A,ARFGAP1,CHMP2A,PDCD6IP,RNF41

FDR, false discovery rate; TCA, tricarboxylic acid; tRNA, trnaser ribonucleic acid; RNA, ribonucleic acid

Transcriptional regulatory relationships between DEGs and TFs {#section19-2046-3758.612.BJR-2017-0102.R1}
-------------------------------------------------------------

Regulatory relationships were predicted between top 20 DEGs (ten up-regulated and ten down-regulated) and TFs, and the regulatory network was established and visualised by Cytoscape software (Cytoscape Corporation) ([Fig. 1](#fig1-2046-3758.612.BJR-2017-0102.R1){ref-type="fig"}). In this network, there were 6038 interactions pairs involving 88 TFs. The top seven TFs covering the most downstream genes were FOXD3, Nkx2-5, Pax-4, Oct-1, HNF-4, Pax-6 and COMP1.

![Transcription factors (TFs)-differentially expressed genes interaction networks. Rectangles and ellipses represent the TFs and target genes, respectively. The red and green colors represent up-regulation and down-regulation, respectively.](bonejointres-06-640-g001){#fig1-2046-3758.612.BJR-2017-0102.R1}

qRT-PCR {#section20-2046-3758.612.BJR-2017-0102.R1}
-------

Among the identified DEGs, VPS35, FCGR2A, TBCA, HIRA, TYROBP and JUND were selected to verify the integrated result. The qRT-PCR results showed that TYROBP and JUND were up-regulated, while VPS35, FCGR2A, TBCA and HIRA were down-regulated. The expression of TBCA, HIRA and TYROBP were consistent with integrated analyses except VPS35, FCGR2A and JUND. The qRT-PCT results are shown in [Figure 2](#fig2-2046-3758.612.BJR-2017-0102.R1){ref-type="fig"}.

![Validation of differentially expressed genes (DEGs) in the osteoporosis blood by quantitative reverse transcriptase-polymerase chain reaction. \*p \< 0.05, †p \< 0.01.](bonejointres-06-640-g002){#fig2-2046-3758.612.BJR-2017-0102.R1}

ROC curve analysis {#section21-2046-3758.612.BJR-2017-0102.R1}
------------------

We performed ROC curve analyses and calculated the AUC to assess the discriminatory ability of DEGs (VPS35, HIRA, PHF20 and NFKB2) in data set GSE56815. The AUC of four DEGs including VPS35 (0.789), HIRA (0.77), PHF20 (0.851) and NFKB2 (0.741) was \> 0.7 ([Fig. 3](#fig3-2046-3758.612.BJR-2017-0102.R1){ref-type="fig"}). PHF20 had the largest AUC among these four DEGs. For the diagnosis of osteoporosis, the sensitivity (proportion of true positives) and 1-specificity (proportion of false positives) of VPS35 was 52.5% and 92.5%, respectively; the sensitivity and 1-specificity of HIRA was 60% and 87.5%, respectively; the sensitivity and 1-specificity of PHF20 was 77.5% and 85%, respectively; and the sensitivity and 1-specificity of NFKB2 was 67.5% and 75%, respectively.

![The receiver operating characteristic (ROC) curves of a) VPS35, b) HIRA, c) PHF20 and d) NFKB2 between osteoporosis patients and healthy controls. The ROC curves were used to show the diagnostic ability of these selected differentially expressed genes (DEGs) with 1-specificity (x-axis; the proportion of false positives) and sensitivity (y-axis; the proportion of true positives).](bonejointres-06-640-g003){#fig3-2046-3758.612.BJR-2017-0102.R1}

Discussion {#section22-2046-3758.612.BJR-2017-0102.R1}
==========

Osteoporosis is a complex disease that is characterised by reduced bone mass and the deterioration of bone-tissue microarchitecture, ultimately leading to increased risk of fractures.^[@bibr24-2046-3758.612.BJR-2017-0102.R1]^ In the present study, we identified 855 up-regulated and 465 down-regulated genes in blood samples of osteoporosis patients compared with control groups. It is well known that osteoclast formation and activation are critical events in maintaining the normal bone mass and structure. Herein, GO and KEGG analyses indicated that these DEGs were significantly involved in osteoclast differentiation, which demonstrated the important role in osteoclast development of osteoporosis. Additionally, the TF-DEGs regulatory network was constructed involving top 20 (ten up-regulated and ten down-regulated) genes and 88 TFs, which further illustrated the role of these DEGs under the regulation of TFs in osteoporosis. Finally, qRT-PCR *in vitro* validated the expression patterns of several genes including VPS35, FCGR2A, TBCA, HIRA, TYROBP and JUND. Some results have been inconsistent with the microarray analyses, probably because of the heterogeneity of the studies, including different inclusion criteria and the small number of patients in the validation set. In summary, ten genes including VPS35, FCGR2A, TBCA, HIRA, TYROBP, JUND, PHF20, NFKB2, RPL35A and BICD2 were considered to play a potential role in the pathology of osteoporosis.

It has been reported that VPS35 is highly expressed in osteoclasts as well as osteoblasts and loss of function will increase hyper-resorptive osteoclast formation.^[@bibr25-2046-3758.612.BJR-2017-0102.R1]^ Specific VPS35 knockdown in the osteoblast lineage resulted in mildly lowered bone mass in the primary spongiosa.^[@bibr26-2046-3758.612.BJR-2017-0102.R1]^ Our study found up-regulated expression of VPS35, which indicated that it may function in the regulation of osteoclast and osteoblast activity in osteoporosis. In addition, VPS35 had significant diagnostic value for osteoporosis, which may serve as a diagnostic biomarker of osteoporosis. FCGR2A has been reported to be related to rheumatoid arthritis and is a target gene of drugs in rheumatoid arthritis treatment.^[@bibr27-2046-3758.612.BJR-2017-0102.R1],[@bibr28-2046-3758.612.BJR-2017-0102.R1]^ It has been indicated that FCGR2A is also associated with ankylosing spondylitis and axial spondyloarthritis.^[@bibr29-2046-3758.612.BJR-2017-0102.R1]^ In the current study, we found an increased expression of FCGR2A in osteoporosis, suggesting that FCGR2A may be associated with the pathology of osteoporosis.

In human cell lines, TBCA knockdown will decrease a mass of a- and b-tubulin levels, subtle changes in the microtubule cytoskeleton and cell death.^[@bibr30-2046-3758.612.BJR-2017-0102.R1]^ Herein, it is down-regulated in osteoporosis blood samples compared with controls. Therefore, we suggest that TBCA may participate in the formation process of cytoskeleton in osteoporosis. HIRA has been recorded associated with H3.3-containing nucleosomes in transcriptional active genomic loci in bone tumours.^[@bibr31-2046-3758.612.BJR-2017-0102.R1]^ In this study, we found that HIRA was down-regulated in osteoporosis blood samples, which suggested that HIRA may play a significant role in histone modification in bone development in osteoporosis. In addition, HIRA has diagnostic value for osteoporosis, suggesting that HIRA may be associated with the pathology of osteoporosis and may serve as a diagnostic biomarker of osteoporosis.

TYROBP is a protein involved in osteoclast differentiation and function, such as the generation of the actin cytoskeleton, which is important for bone resorption.^[@bibr32-2046-3758.612.BJR-2017-0102.R1]^ In the current study, the expression of TYROBP was up-regulated, indicating that it may play a vital role in the regulation of osteoclast differentiation in osteoporosis. JUND has proven to control bone formation, osteoblast proliferation, and differentiation.^[@bibr33-2046-3758.612.BJR-2017-0102.R1]-[@bibr36-2046-3758.612.BJR-2017-0102.R1]^ Furthermore, it is a DEG in mesenchymal stem cells in osteoporosis.^[@bibr37-2046-3758.612.BJR-2017-0102.R1]^ Our results showed that JUND was expressed differentially in osteoporosis, which demonstrated the essential role of JUND in bone formation and osteoporosis.

It has been reported that PHF20-null mice show delay in bone formation, defects in skeletal composition and haematopoiesis.^[@bibr38-2046-3758.612.BJR-2017-0102.R1]^ We found that PHF20 was up-regulated, suggesting that PHF20 may play a role in bone development through different mechanisms or signal pathways in human osteoporosis. It is noted that PHF20 had a significant diagnostic value for osteoporosis, which may be considered as a biomarker in osteoporosis diagnosis. NFKB2 is reported up-regulated under estrogen treatment in needle bone biopsies of osteoporosis.^[@bibr39-2046-3758.612.BJR-2017-0102.R1]^ Additionally, it is a key gene in the TRAIL pathway for osteoporosis fractures.^[@bibr40-2046-3758.612.BJR-2017-0102.R1]^ It is noted that bone resorption marker TRAP5b was undetectable in *Nfkb2*^+/--^ and *Nfkb2*^--/--^ mice, and was slightly but significantly increased by TNF injection in *Nfkb2*^+/--^ mice,^[@bibr41-2046-3758.612.BJR-2017-0102.R1]^ which suggested the relationship between NFKB2 and bone resorption. Moreover, our study revealed that NFKB2 was significantly enriched in osteoblast differentiation, which further indicated that it was an essential molecule in bone metabolism. Additionally, we found that NFKB2 was remarkably associated with diagnosis and may play a valuable role in the clinical and laboratory diagnosis of osteoporosis.

RPL35A participates in cytoplasmic ribosomal protein pathways in osteoarthritis chondrocytes.^[@bibr42-2046-3758.612.BJR-2017-0102.R1]^ In addition, it is linked to inherited bone marrow failure syndromes.^[@bibr43-2046-3758.612.BJR-2017-0102.R1]^ Herein, we found that RPL35A was down-regulated in osteoporosis blood samples compared with normal controls, which provided another pathogenic role in bone disease. BICD2 mutation is involved in spinal muscular atrophy.^[@bibr44-2046-3758.612.BJR-2017-0102.R1]-[@bibr47-2046-3758.612.BJR-2017-0102.R1]^ Moreover, it has been reported that mutations in BICD2 will cause early onset non-length dependent lower-limb predominant weakness and contractures.^[@bibr48-2046-3758.612.BJR-2017-0102.R1]^ In the present study, we found decreased expression of BICD2 in osteoporosis, suggesting the vital role in bone formation and metabolism.

There are limitations to our study. First, the sample size in the qRT-PCR data set was small and larger numbers of blood samples of osteoporosis patients are needed for further research. Secondly, the deregulated DEGs in osteoporosis were identified and the definite biological function was not investigated in our study. *In vivo* and *in vitro* experiments are essential for elucidation of the biological roles of DEGs in osteoporosis in future work.

In summary, we identified several key genes including VPS35, FCGR2A, TBCA, HIRA, TYROBP, JUND, PHF20, NFKB2, RPL35A and BICD2 involved in the regulation of bone formation and metabolism under the regulation of TFs (FOXD3, Nkx2-5, Pax-4, Oct-1, HNF-4, Pax-6 and COMP1) in osteoporosis. It is noted that VPS35, HIRA, PHF20 and NFKB2 had significant diagnostic value for osteoporosis and may serve as diagnostic biomarkers of osteoporosis. Our results may provide important information for studying the pathogenic mechanisms and consequences of osteoporosis.
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